CVS will add Zepbound coverage on Oct. 1, and start covering Lilly's newly approved Foundayo pill on June 1.

The pharmacy benefit manager dropped Zepbound a year ago in favor of rival Wegovy — now both Lilly and Novo Nordisk drugs will be co-preferred options ...

CVS Health will restore Eli Lilly’s weight-loss injection Zepbound to its list of covered drugs and also add the drugmaker’s newly approved obesity pill, Foundayo, it said today.

CVS Health’s decision to expand formulary coverage for key GLP-1 therapies marks a boost for Eli Lilly's obesity drug ...

CVS Caremark, one of America’s most powerful pharmacy benefit managers, will begin covering more GLP-1 medications again later this year, potentially expanding access to the blockbuster weight-loss ...

Zepbound (tirzepatide) and Mounjaro (tirzepatide) are prescription drugs used to treat different conditions. Zepbound and Mounjaro are not available as generic drugs. The two drugs have some ...

Mounjaro and Zepbound are two brand-name glucagon-like peptide-1 (GLP-1) medications manufactured by Eli Lilly. Although they contain the same active ingredient, tirzepatide, and may affect blood ...

Tirzepatide is an injectable medication that mimics two gut hormones: dual glucagon-like peptide-1 (GLP-1) and ...

Patients, doctors and investors will soon learn a lot more about a new, more convenient treatment that could shake up the booming weight loss drug market. Stream Connecticut News for free, 24/7, ...

Eli Lilly will begin offering its popular new weight-loss drug Zepbound in vials—in addition to standard injection-pen devices—at about half the price of the original for certain doses. To date, ...

Patients, doctors and investors will soon learn a lot more about a new, more convenient treatment that could shake up the booming weight loss drug market. Analysts expect the pill to be as effective, ...